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Abstract:  27 
Streptococcus agalactiae (group B Streptococcus, GBS) is a leading cause of sepsis in 28 
neonates. The rate of invasive GBS disease in non-pregnant adults also continues to climb. 29 
Aminoglycosides alone have little or no effect on GBS, but synergistic killing with penicillin 30 
has been shown in vitro. High-level gentamicin resistance (HLGR) in GBS isolates, however, 31 
leads to loss of a synergistic effect. We therefore performed a multicentre study to determine 32 
the frequency of HLGR GBS isolates and to elucidate the molecular mechanisms leading to 33 
gentamicin resistance. From eight centres in four countries, 1128 invasive and colonizing 34 
GBS isolates were pooled and investigated for the presence of HLGR. We identified two 35 
strains that displayed HLGR (BSU1203 and BSU452), both of which carried the aacA-aphD 36 
gene, typically conferring HLGR. Though, only one strain (BSU1203) also carried the 37 
previously described chromosomal gentamicin resistance transposon, designated Tn3706. In 38 
the other strain (BSU452), plasmid purification and subsequent DNA sequencing resulted in 39 
the detection of plasmid pIP501 carrying a remnant of a Tn3 family transposon. Its ability to 40 
confer HLGR was proven by transfer into an Enterococcus faecalis isolate. Conversely, loss 41 
of HLGR was documented after curing both GBS BSU452 and the transformed E. faecalis 42 
strain from the plasmid. This is the first report showing a plasmid mediated HLGR in GBS. 43 
Thus, in our clinical GBS isolates HLGR is mediated both chromosomally and 44 
extrachromosomally. 45 
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 52 
Introduction 53 
Streptococcus agalactiae, alternatively designated group B Streptococcus (GBS), is a leading 54 
cause of morbidity and mortality in neonates and pregnant women. Recommendations for 55 
diagnosing maternal GBS colonization and administering intrapartum antimicrobial 56 
prophylaxis have led to a significant decrease in these infections (1). The rate of invasive 57 
GBS disease in non-pregnant adults, however, continues to climb (2). Elderly persons and 58 
those with underlying diseases – two expanding segments of the population – are at increased 59 
risk (3). Treatment concepts for invasive GBS infections in non-pregnant adults have not been 60 
established. Clinical isolates of GBS are susceptible to penicillin, the antimicrobial agent of 61 
choice for treating invasive diseases. Several publications advocate the addition of an 62 
aminoglycoside to penicillin or ampicillin for infective endocarditis (4) and periprosthetic 63 
joint infections (5), although aminoglycosides have ototoxic and nephrotoxic side effects, in 64 
particular in the elderly. Aminoglycosides alone have little or no effect on GBS, but 65 
synergistic killing with penicillin has been shown in vitro (6). In case of the presence of high-66 
level gentamicin resistance (HLGR) in a bacterial isolate, there is a lack of a synergistic 67 
effect.   68 
While HLGR in Enterococcus spp. is frequently found (7), to the best of our knowledge, only 69 
two HLGR GBS strains have been previously reported (8, 9). Most diagnostic laboratories do 70 
not test routinely for HLGR in GBS. Thus, little is known about the frequency of HLGR 71 
GBS, the mechanisms of acquiring HLGR and the potential to spread genetic elements 72 
associated with HLGR.  73 
The aim of this study was to estimate the frequency of HLGR GBS isolates (i) in 74 
systematically and continuously collected GBS isolates from colonized pregnant and non-75 
pregnant women and (ii) in GBS isolates pooled in a collection that stems from various 76 
selected patient populations. Upon detection of HLGR isolates, we elaborated the molecular 77 
mechanism conferring this resistance.   78 
Materials and Methods 79 
GBS isolates 80 
The study consisted of 1128 GBS isolates. Of these, 464 (41%) were pooled from various 81 
GBS collections (Table 1). These isolates stem from various centres and were previously 82 
investigated in another context (10-15). The other 664 (59%) GBS isolates were prospectively 83 
collected and screened for the presence of HLGR. The origin of GBS isolation, the 84 
association with diseases or colonization, and the sampling period are presented in Table 1. 85 
Definition and identification of HLGR in GBS 86 
No definition of HLGR in GBS has been published. According to the recommended screening 87 
tests for the detection of HLGR in Enterococcus spp., the resistant isolates have an MIC ≥500 88 
mg/L (16). In addition, HLGR isolates with an MIC >500 mg/L have been reported (17, 18). 89 
Therefore, HLGR in GBS was defined when the gentamicin MIC determined by Etest was 90 
≥512 mg/L. All MIC determinations were confirmed with ≥3 measurements.  91 
Two different methods for the identification of HLGR in GBS were applied. Five hundred 92 
sixty-one isolates (49.7%) were plated on Mueller Hinton agar supplemented with 256 mg/L 93 
of gentamicin. Subsequently, the MIC of growing GBS colonies was determined by Etest. For 94 
567 (50.3%) isolates, the MIC was primarily determined by Etest without a prior HLGR 95 
screening test.  96 
Bacterial strains  97 
The strains used in this study are presented in Table 2. The plasmid-free recipient used in the 98 
mating experiments was E. faecalis (BSU386), a clinical blood culture isolate without HLGR. 99 
Genetic basis of HLGR 100 
Standard recombinant DNA techniques were used for nucleic acid preparation and analysis. 101 
Plasmid DNA was isolated and purified using the QIAprep Spin Miniprep Kit (QIAGEN, 102 
Hilden, Germany), according to the manufacturer’s instructions. PCR was performed with 103 
Taq polymerase according to the manufacturer’s protocol (Roche Diagnostics, Mannheim, 104 
Germany), with 35 cycles of amplification steps consisting of 1 min at 94°C, 1 min at 55°C 105 
and 1 min at 72°C. PCR products were sequenced on an ABI PRISM 310 Genetic Analyzer, 106 
using the ABI PRISM BigDye Terminator v1.1 Cycle Sequencing Kit (Applied Biosystems, 107 
Weiterstadt, Germany). To identify HLGR resistance gene, we performed multiplex PCR as 108 
described by Vakulenko et al.(19). For the detection of Tn3706 specific nucleotide sequences, 109 
we used PCR with the primers O1, O2 and O3, as described by Horaud et al (20). The primers 110 
used for this study are presented in Table 3. Detection of open reading frames (ORFs) was 111 
carried out by using ORF Finder (http://www.ncbi.nlm.nih.gov/gorf/gorf.html).  Sequence 112 
comparison was performed by using the BLAST system 113 
(http://www.ncbi.nlm.nih.gov/BLAST/). Nucleotide sequences were submitted to GenBank 114 
under the accession number (KP698941). 115 
Transfer and mobilization of the genetic element conferring HLGR 116 
To investigate the potential transfer of resistance, we transformed E. faecalis (BSU386) with 117 
plasmid DNA, as described previously (21). Curing the transformed E. faecalis strain and 118 
GBS BSU452 with HLGR was achieved as follows. The strains were exposed in an overnight 119 
culture to serial twofold dilutions of ciprofloxacin in Todd Hewitt broth plus 0.5% yeast 120 
extract and Luria-Bertani medium. Bacterial cultures containing the highest subinhibitory 121 
concentration of ciprofloxacin (i.e. 0.625 mg/L for GBS BSU452 and 10 mg/L for E. faecalis 122 
BSU580) were plated on antibiotic-free tryptic soy agar blood plates and grown overnight at 123 
37°C. Single colonies were then tested for loss of resistance to gentamicin by subculturing 124 
onto Mueller Hinton agar plates containing 256 mg/L gentamicin. The MIC for gentamicin 125 
was then determined by Etest.  126 
 127 
 128 
 129 
 130 
Results 131 
GBS isolates with HLGR 132 
Among 1128 GBS isolates, two (0.17%) strains with HLGR were identified. One strain 133 
(BSU1203, MIC >1024 mg/L) was obtained from a 35-year-old Swiss woman during prenatal 134 
screening. The second HLGR GBS strain (BSU452, MIC 512 mg/L) was isolated in a 135 
respiratory specimen from a 26-year old man with cystic fibrosis. 136 
PCR detection of genes conferring HLGR in GBS 137 
To investigate the resistance determinants in HLGR GBS strains, we performed PCRs that 138 
were specific for the aac(6’)-Ie-aph(2”)-Ia gene and the flanking IS256 element (19). The 139 
aac(6’)-Ie-aph(2”)-Ia gene was readily detected in both strains, yielding the expected product 140 
of 348 bp (19). 141 
Detection of an old transposon and a novel element 142 
A PCR with a primer set annealing on the structural gentamicin resistance gene and the IS256 143 
sequence, located downstream of this gene, showed the expected 369-bp product for strain 144 
GBS BSU1203 (19), indicating the presence of the previously described chromosomal 145 
transposon Tn3706. For further characterization of the resistance determinant, PCRs that were 146 
specific for insertion sequence elements of Tn3706 were performed, as published previously 147 
(20). These PCRs were positive in GBS strain BSU1203 and matched those previously 148 
described in HLGR GBS strain B128 (20), confirming the presence of Tn3706. In GBS strain 149 
BSU452 the aac(6’)-Ie-aph(2”)-Ia gene was found, but none of the PCR reactions specific for 150 
the transposon structures of Tn5281, Tn4001 or Tn3706 (20), yielded a product, suggesting 151 
the presence of a novel HLGR resistance determinant in this strain.  152 
Characterization of a novel mobile genetic element conferring HLGR in GBS 153 
To identify the genetic structure of GBS strain BSU452 carrying the aac(6’)-Ie-aph(2”)-Ia 154 
gene, we performed an inverse PCR on a plasmid preparation of BSU452. Primers annealing 155 
to the gentamicin resistance gene (Table 3) and directed towards DNA regions upstream and 156 
downstream of aac(6’)-Ie-aph(2”)-Ia and yielded a PCR product about 2 kb in length, which 157 
was completely sequenced. Nucleotide comparison with the GenBank database revealed a 158 
100% identity of nucleotides 1-253 and 721-2029 with plasmid pTEF1 of E. faecalis strain 159 
V583 (AE016833.1). Several ORFs were identified on the 2 kb PCR product and comparison 160 
of the deduced amino acids with the GenBank database revealed a DNA resolvase fragment 161 
and one copy of an insertion sequence element with high homology to IS1216. This structure 162 
displayed high similarities to a Tn3 family transposon.  163 
Transfer and mobilization of the resistance determinant in association with HLGR 164 
The HLGR resistance genes and the flanking DNA sequences in GBS BSU1203 matched 165 
those previously identified in GBS B128, and because thorough molecular analyses on the 166 
acquisition of HLGR have been published for that strain (8, 22, 23), further investigations 167 
focussed on GBS BSU452. Tn3 family transposons are typically located on plasmids. To 168 
investigate if this is the case in strain GBS BSU452 and to characterize the potential of 169 
spreading HLGR to other isolates, we transformed the gentamicin susceptible E. faecalis 170 
strain BSU386 with the plasmid preparation obtained from GBS BSU452. Positive clones (i.e. 171 
designated E. faecalis BSU580, which carries the mobile element of BSU452) were obtained 172 
upon plating the transformed strain onto the HLGR screening agar, as described above. A 173 
subsequent gentamicin evaluation revealed an increase in MIC from 12 mg/L to >1024 mg/L 174 
(Table 2). To ensure that the increased MIC was due to the uptake of the plasmid DNA, 175 
plasmid preparations were subjected to gel electrophoresis (Figure 1), which showed the 176 
presence of large plasmids in the HLGR strains BSU452 and BSU580. Further confirmation 177 
of the successful transfer was achieved by PCR showing the presence of the aac(6’)-Ie-178 
aph(2”)-Ia gene and a lack of any flanking IS256 sequences in E. faecalis strain BSU580. To 179 
confirm that the newly detected mobile genetic element is indeed located on a plasmid, we 180 
attempted to cure GBS BSU452 and the transformed E. faecalis BSU580 from the plasmid. 181 
This was successfully achieved by growing the strains in subinhibitory conditions of 182 
ciprofloxacin, as described by Eliopoulos et al. (24). Under these conditions, clones of both 183 
GBS BSU452 and the transformed E. faecalis strain BSU580 lost their elevated resistance to 184 
gentamicin. The MICs decreased in GBS strain BSU729 (i.e. strain BSU452 after plasmid 185 
curing) from 512 mg/L to 24 mg/L and in E. faecalis BSU720 (i.e. strain BSU580 after 186 
plasmid curing) from >1024 mg/L to 12 mg/L (Table 2). In addition, the lack of a plasmid in 187 
the cured strains could be demonstrated by gel electrophoresis (Figure 1). Plasmid loss in the 188 
presence of subinhibitory ciprofloxacin occurred at a frequency of about 0.02% (1 in 4500 189 
colonies in GBS and 1 in 6000 colonies of E. faecalis). One of the most commonly found 190 
plasmids in GBS and enterococci is pIP501. To determine, if the detected plasmid is pIP501, 191 
the plasmid preparation obtained from GBS BSU 452 was subjected to PCR as detailed 192 
elsewhere (25). PCR products were sequenced and the presence of pIP501 in GBS BSU 452 193 
confirmed.  194 
 195 
Discussion 196 
In contrast to screens for Enterococcus spp., GBS surveillance schemes usually do not include 197 
gentamicin susceptibility testing, and screening for HLGR is often omitted in clinical 198 
laboratories. The prevalence of HLGR in GBS is, therefore, unknown. Previously, two HLGR 199 
GBS strains were reported. One of them (B128) was isolated from an infected leg wound in 200 
1987 (8), the other from a 49-year-old woman with a urinary tract infection, published in 201 
2002 (9). We identified two further colonizing strains in a collection of over 1000 isolates 202 
(0.17%). This proportion is in contrast to a previously published Argentinian study (18). 203 
Among 141 strains, the authors found 13.5% HLGR GBS. Although no firm epidemiological 204 
conclusion about the frequency of HLGR isolates can be made on the basis of these two 205 
studies, it should be noted that up to 20% – 35% of women are colonized with GBS (26), and 206 
that the absolute number of HLGR GBS isolates may be much higher than previously 207 
estimated (27). Thus, for a patient receiving penicillin-gentamicin combination therapy for 208 
invasive GBS infection, and considering the potential side effects of aminoglycosides, the 209 
presence of HLGR is of significant clinical relevance.   210 
Investigations on the genetic basis for HLGR in E. faecalis led to the identification of the 211 
aacA-aphD gene (28). It is typically found on the composite transposon Tn5281. The 212 
transposon resembles Tn4001 in Staphylococcus aureus and is characterized by the presence 213 
of two IS256 copies flanking the transposon structure. The aacA-aphD gene, later designated 214 
aac(6’)- aph(2”), encodes a bifunctional enzyme with an acetyltransferase and a 215 
phosphotransferase function. The enzyme catalyzes inactivation of the vast majority of 216 
aminoglycosides with the exception of streptomycin. In most Enterococcus spp. with HLGR, 217 
the transposon harbouring the aac(6’)- aph(2”) gene is found on a plasmid (29). Truncated 218 
forms of Tn4001 are typically located on plasmid DNA (30). Intact Tn4001 transposons can 219 
also be located on chromosomal DNA. In the previously described HLGR GBS strain B128, 220 
the aacA-aphD gene was found on a Tn4001 derivative (designated Tn3706), located on 221 
chromosomal DNA (8). In one of our strains (BSU1203), the finding of transposon Tn3706 222 
conferring HLGR is in agreement with the previously published findings about HLGR GBS 223 
strain B128 (8, 22, 23)). Horaud et al. (23) described that its transposition from E. faecalis 224 
occurred on GBS plasmid pIP501. However, after conjugative transfer between GBS strains, 225 
the hybrid replicons pIP501::Tn3706 were found to be structurally unstable. This observation 226 
indicated that streptococcal pIP501-like plasmids do not constitute appropriate delivery 227 
vectors for the dissemination of Tn3706 among GBS, and therefore, HLGR is found relatively 228 
rarely among GBS (23). Although these arguments speak against a high potential for spread, 229 
the persistence of HLGR in GBS128 and BSU1203 indicates that Tn3706 can be stably 230 
integrated into the chromosome.  231 
In GBS BSU452, we identified a different mobile genetic element. The genes surrounding the 232 
aac(6’)- aph(2”) gene did not display the structures of transposon Tn4001, or any of the 233 
closely related derivatives or its truncated forms. We detected plasmid pIP501, which is a 234 
conjugative plasmid that often carries multiresistance genes. It has previously been described 235 
in S. agalactiae in association with HLGR and belongs to the Inc18 group of plasmids (25). 236 
Tn3 family transposons are commonly associated with Inc18 plasmids and often confer 237 
antibiotic resistance in Enterococcus spp. (31). They are, however, typically associated with 238 
glycopeptide and macrolide resistance (32) and not HLGR. Investigators have previously 239 
reported the presence of an IS1216 transposase on Tn3-like remnants,(33) as we found in our 240 
GBS BSU452 strain; however, IS1216 is typically associated with tetracycline resistance in 241 
streptococcal species (34). To the best of our knowledge, the detection of the aacA-aphD gene 242 
on a Tn3-like transposon and the presence of IS216 in association with HLGR is a novel 243 
finding. It has been reported neither for enterococci nor for GBS.  244 
The resistance determinant in GBS BSU452 shows close homologies to parts of the 245 
enterococcal resistance plasmid pTEF1 of the E. faecalis strain V583 (35), suggesting that it 246 
may have been transferred through horizontal gene transfer. This is, however, speculative for 247 
GBS strain BSU452, since the presence of a HLGR Tn3-like transposon in GBS has not been 248 
previously described. Nevertheless, horizontal gene transfer of resistance genes from 249 
Enterococcus spp. to other gram-positive bacteria by mobile genetic elements is a well-250 
described mechanism in the spread of antibiotic resistance (31, 32). Horizontal gene transfer 251 
has recently been suggested for the acquisition of vancomycin resistance genes in GBS (36). 252 
GBS strain BSU452 was isolated from the sputum of a cystic fibrosis patient, but there was 253 
no evidence of enterococcal colonization. Considering that patients with cystic fibrosis are 254 
often treated with antibiotics (including aminoglycosides), and their microbiome in the 255 
respiratory tract is different from that of untreated healthy patients, it is possible that 256 
horizontal gene transfer to GBS originated from the selected flora. However this hypothesis 257 
cannot be proven in our case and remains speculation. Though, a plasmid-borne HLGR has 258 
high potential for further spread in a GBS population, the concern of this phenomenon cannot 259 
be predicted yet. In this study, we demonstrated that pIP501, including the HLGR resistance 260 
determinant of GBS452, could easily be transferred to E. faecalis. Thus, it is conceivable that 261 
transfer to other GBS isolates is also possible, especially in view of the fact that pIP501 is a 262 
broad host range plasmid, well established in GBS and enterococci.  263 
In conclusion, the overall frequency of HLGR GBS in our large collection of isolates was 264 
low. Molecular investigations revealed a transposon located on the chromosome, as 265 
previously described in a single isolate, (8, 22, 23) and a Tn3 family transposon conferring 266 
HLGR in association with pIP501. These findings point towards a new dimension of potential 267 
spread of HLGR within GBS. 268 
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407 
Table 1. The pooled collection of isolates investigated for the presence of high-level gentamicin resistance  408 
Refa na Disease/Case definition Origin of GBS isolation Study type Collection 
periods 
Geographic origin HLGR 
(10) 75 No disease/colonization Vaginal and rectal swabs from 
pregnant and non-pregnant 
women 
Cross-sectional study 2001 – 2003 Aachen and 
Munich, Germany
0 
(12) 60 EOD with invasive neonatal 
GBS infections 
Isolation of GBS from blood or 
CSF and other sterile body fluids 
Part of the prospective active 
surveillance study 
2001 – 2003 Freiburg, Germany 0 
(13) 50b Suspicion of EOD without 
proven invasive GBS disease
GBS isolates from non-sterile sites Part of the prospective active 
surveillance study 
2001 – 2003 Freiburg, Germany 0 
(14) 30 Patients with cystic fibrosis Respiratory samples Collection of isolatesc 2002 – 2008 Münster, Germany 1 
(11) 150 No disease/colonization Rectovaginal specimens from 
pregnant and non-pregnant 
women 
Part of the national 
surveillance study 
2005 – 2009 Lisbon, Portugal 0 
- 97 No disease/colonization Vaginal swabs from pregnant and 
non-pregnant women 
- d 2009 Ulm, Germany 0 
(15) 99 No disease/colonization Vaginal swabs from pregnant and 
non-pregnant women 
Cross-sectional study 2010 Ismailia, Egypt 0 
(37) 364 No disease/colonization Vaginal swabs from pregnant 
women 
Cross-sectional study 2009 – 2010 Bern, Switzerland 1 
- 203 Invasive group B 
Streptococcus infections 
Isolation of GBS from blood, CSF 
and other sterile body fluids 
- e 1998 – 2013 Bern, Switzerland 0 
Total 1128      2 
GBS, Group B Streptococcus; HLGR, high-level gentamicin resistance; Ref, reference; n, number of GBS isolates; EOD, early-onset disease. 409 
a GBS isolates investigated and published in a context other than the presence of HLGR. The number of GBS isolates investigated for HLGR may 410 
vary from the number in the source publication for technical reasons. 411 
b For this study, only GBS isolates with serotype III were available. 412 
c GBS isolation occurred during a routine visit or during a visit due to an exacerbation of clinical symptoms. 413 
d Prospective collection during routine diagnostic microbiology laboratory analysis. GBS isolates were investigated for this study. 414 
e Collection of invasive GBS isolates (all age groups) during routine diagnostic microbiology laboratory analysis. GBS isolates were investigated for 415 
this study. 416 
 417 
 418 
Table 2. Bacterial strains and their corresponding genetic elements conferring HLGR 419 
Species Strain Description MIC gentamicin aac(6’)-Ie-
aph(2”) 
-Ia gene 
Transposon 
GBS BSU1203 wild-type strain ≥1024 mg/L yes Tn3706 
GBS BSU452 wild-type strain 512 mg/L yes Tn3-like 
E. faecalis BSU386 wild-type strain  12 mg/L no no 
E. faecalis BSU580 BSU386 + pIP501BSU452 ≥1024 mg/L yes Tn3-like 
E. faecalis BSU720 BSU580 cured 12 mg/L no no 
GBS BSU729 BSU452 cured 24 mg/L no no 
GBS, Group B Streptococcus; HLGR, high-level gentamicin resistance. 420 
 421 
 422 
 423 
 424 
Table 3. Primers used for PCR and DNA sequencing 425 
Name  Sequence (5’- 3’) Target gene 
Inverse primer 
HLGR1 
CTT CAT CTT CCC AAG GCT CTG aac(6’)- aph(2”) 
Inverse primer 
HLGR2 
GCC AGA ACA TGA ATT ACA CGA GG aac(6’)- aph(2”) 
369 Vakulenko PCR CAGGAATTTATCGAAAATGGTAGAAAAG  
369 Vakulenko PCR CACAATCGACTAAAGAGTACCAATC  
348 Vakulenko PCR CAGAGCCTTGGGAAGATGAAG  
348 Vakulenko PCR CCTCGTGTAATTCATGTTCTGGC  
Primer O1 GGACCTACATGATGAATGGA  
Primer O2 CCTTTACAGAATATTCAATAATGC  
Primer O3 
pIP501-for 
pIP501-rev 
GTATAG CAATATGCAAATCC 
TCGCTCAATCACTACCAAGC 
CTTGAACGAGTAAAGCCCTT 
 
 426 
 427 
 428 
 429 
 430 
 431 
 432 
 433 
 434 
 435 
 436 
Figure 1. Plasmid preparations of GBS and E. faecalis strains.  437 
Shown are plasmid preparations of E. faecalis and GBS strains separated by agarose gel 438 
electrophoresis (0.8 % gel). 1: E. faecalis strain BSU386 (wild-type strain without HLGR). 2: 439 
E. faecalis strain BSU 580 (wild-type strain BSU386 after transformation with plasmid 440 
preparation from S. agalactiae strain BSU452, displaying HLGR). 3: E. faecalis strain 441 
BSU720 (E. faecalis strain BSU580 after plasmid curing and loss of HLGR). 4: S. agalactiae 442 
strain BSU452 (patient isolate displaying HLGR). 5: S. agalactiae strain BSU729 (S. 443 
agalactiae strain BSU452 after plasmid curing and loss of HLGR). M: molecular size marker.  444 
 445 

